CrenoGIST– A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Crenolanib in Subjects with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene
The purpose of this study is to compare the safety and effects of crenolanib (the study drug) on people and their risk of gastrointestinal stroma tumors (GIST) cancer. In this study, you will get either the study drug or placebo, a pill that looks like the study drug but has no real medicine in it.
>18 years of age diagnosed with GIST with a D842V mutation. Various other tests, procedures, and exams will be done to confirm eligibly.
18 - 120
Healthy Volunteers Needed
Duration of Participation
For as long as you are seeing benefit from the study drug.
Knight Clinical Trials Information Line
Arog Pharmaceuticals Inc.